Anti-inflammatory Against CV Events and Cancer

Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS)

RACE 3 study; The Routine versus Aggressive upstream rhythm Control for prevention of Early persistent atrial fibrillation in heart failure study

ALBATROSS and REMINDER trials

Mechanism for benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of ≥160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Rivaroxaban in stable peripheral or carotid artery disease

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Catheter Ablation versus Standard conventional Treatment in patients with Left ventricular dysfunction and Atrial Fibrillation The CASTLE-AF trial

The long-term follow-up of patients in the NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study

Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: The AFFIRM Study

Determination of the role of Oxygen in suspected Acute Myocardial Infraction

Apixaban vs. Heparin/Vitamin K Antagonist in Anticoagulation-naive Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial

Investigation of catheter-based renal denervation in patients with uncontrolled hypertansion in the absence of antihypertensive medications: Three-month results from the randomized, sham-controlled, proof of concept SPYRAL HTN-OFF MED trial

Impact of a 1- or 2-dose starting regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reduction over 1 year

The Left Atrial Appendage Closure by Surgery study (LAACS)

Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein cholesterol

The Clinician’s Perspective

Managing cardiovascular outcomes in patients with type 2 diabetes – Where have we come from and where are we going? And Improving cardiovascular outcomes in patients with type 2 diabetes: our clinical experience with empagliflozin

When to optimize heart failure treatment?

Leading the way to improved stroke prevention with NOACs: focus on AF patients undergoing non-surgical procedures and on subclinical AF

Recent results in clinical trials of blood cholesterol lowering

A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines (TECOS)

Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure

The evidence supporting the use of FFR to guide percutaneous coronary intervention in stable and ACS patients.

The cardiologists' perspective on pulmonary hypertension

Identifying the aspirin patient: interactive case presentations.

Why wait to optimize treatment? / SPYRAL HTN OFF-MED Study P

CANTOS Trial - Anti-inflammatory Agent Against CV Events and Cancer

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)

Redefining anticoagulation in AF ablation: RE-CIRCUIT and RE-VERSE AD / Rewire your thinking on AF ablation: impact of uninterrupted dabigatran